Softwr

Healthcare · head to head

Beckman Coulter DxONE vs Therapixel

Beckman Coulter DxONE logo

Beckman Coulter DxONE

Healthcare

Clinical laboratory middleware and informatics from a diagnostics instrument manufacturer

From
On request
Rated
-
Full reviewWebsite
Therapixel logo

Therapixel

Healthcare

French mammography AI with FDA clearances for 2D and tomosynthesis breast screening

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Beckman Coulter DxONE the rules and quality control workflows are tuned to Beckman analysers, so laboratories with a mixed Roche, Abbott and Siemens fleet get materially less coverage and typically buy vendor neutral middleware such as Data Innovations Instrument Manager instead.; Therapixel european and American regulatory positions were established under different regimes, and under the EU Medical Device Regulation this class of diagnostic AI faces a higher classification and notified body scrutiny, so European buyers must verify the current MDR certificate and expiry rather than relying on a legacy CE reference.
  • They diverge on capability: Beckman Coulter DxONE covers DxONE Command Central, Therapixel covers MammoScreen 2D.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Beckman Coulter DxONE and Therapixel actually diverge.

Attributes where Beckman Coulter DxONE and Therapixel differ
AttributeBeckman Coulter DxONETherapixel
PlatformsWeb, WindowsWeb

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Beckman Coulter DxONE

  • DxONE Command Central
  • DxONE Workflow Manager
  • REMISOL Advance
  • DxONE Inventory Manager
  • Autoverification rules
  • Quality control monitoring
  • LIS interfacing

Only in Therapixel

  • MammoScreen 2D
  • MammoScreen DBT
  • One to ten suspicion score
  • Summary report
  • Workstation and PACS delivery
  • Reading workflow configurations

What people use each for

The jobs each tool is most often brought in to do.

Beckman Coulter DxONE

  • A hospital laboratory standardising on Beckman DxC and DxI analysers that wants autoverification to release the majority of routine chemistry without technologist reviewnot Therapixel
  • A low volume rural laboratory that cannot justify on premises middleware servers and needs a cloud hosted rules enginenot Therapixel
  • A multi site laboratory network that needs identical autoverification rules applied consistently across every site, which REMISOL Advance is built fornot Therapixel
  • A laboratory whose LIS cannot express delta checks or repeat rules and needs that logic to live in middleware insteadnot Therapixel

Therapixel

  • A European breast screening programme running mandatory double reading that wants to evaluate AI as a concurrent or second reader within what national guidance permitsnot Beckman Coulter DxONE
  • An American breast centre that has moved to tomosynthesis and needs reading support on DBT specifically, which Therapixel holds a clearance fornot Beckman Coulter DxONE
  • A screening service wanting a graded suspicion score rather than a binary flag so readers can calibrate their own thresholdnot Beckman Coulter DxONE
  • A radiology group evaluating multiple mammography AI vendors head to head on their own historic case set before committingnot Beckman Coulter DxONE

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Beckman Coulter DxONE

  • The rules and quality control workflows are tuned to Beckman analysers, so laboratories with a mixed Roche, Abbott and Siemens fleet get materially less coverage and typically buy vendor neutral middleware such as Data Innovations Instrument Manager instead.
  • Pricing is bundled into analyser and reagent contracts rather than itemised, so a laboratory cannot compare the informatics cost against a standalone middleware quote and often does not know what it is paying for the software.
  • Because the software is tied to a reagent rental term, the real cost of switching middleware is the remaining years of the reagent commitment, not a software renewal, which locks the laboratory in far longer than a software contract would.
  • DxONE Workflow Manager and REMISOL Advance are different products with different rule engines rather than one product at two sizes, so a laboratory that grows out of Workflow Manager faces a migration and rule rewrite, not an upgrade.
  • Interface builds to the hospital LIS are professional services work quoted per interface, and laboratories consistently underestimate this line, particularly where the LIS is an older Sunquest or SCC installation.

Therapixel

  • European and American regulatory positions were established under different regimes, and under the EU Medical Device Regulation this class of diagnostic AI faces a higher classification and notified body scrutiny, so European buyers must verify the current MDR certificate and expiry rather than relying on a legacy CE reference.
  • MammoScreen does mammography only, so a hospital wanting AI across head CT, chest and breast needs several vendors and several PACS integrations, or an orchestration layer bought from someone else.
  • Therapixel is a small French company competing against Hologic and iCAD, which have incumbency inside the mammography reading workstation, so integration into an American breast centre is more work than it is for the workstation vendor own AI.
  • Detection performance is sensitive to the mammography unit vendor and acquisition protocol, so published results do not transfer between estates and each site needs local validation it must fund itself.
  • Whether AI can substitute for one of two human readers is a national workforce and liability question, not a product capability, so the labour saving that justifies the purchase in one country is not permitted in another.

Pricing, plan by plan

Beckman Coulter DxONE

On request
  • DxONE$undefined/year
    • Quoted as part of an analyser or reagent contract, not as standalone software
    • Priced against instrument fleet size and test volume
    • Multi year reagent rental agreements are the usual commercial vehicle

Therapixel

On request
  • MammoScreen$undefined/year
    • Priced per examination or by annual screening volume
    • 2D and tomosynthesis licensed by the versions cleared for each
    • Cloud or on premises deployment quoted differently

Which should you pick?

Choose Beckman Coulter DxONE if

  • You need dxone command central.
  • You work on Web, Windows.
  • You also want dxone workflow manager.
Beckman Coulter DxONE review

Choose Therapixel if

  • You need mammoscreen 2d.
  • You also want mammoscreen dbt.
Therapixel review

Questions people ask

Is Beckman Coulter DxONE or Therapixel better?
Neither clearly leads. Beckman Coulter DxONE starts at On request and Therapixel at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Beckman Coulter DxONE or Therapixel?
Beckman Coulter DxONE starts at On request and Therapixel at On request.
Does Beckman Coulter DxONE or Therapixel run on more platforms?
Beckman Coulter DxONE runs on Web, Windows. Therapixel runs on Web.
What is Beckman Coulter DxONE best used for?
Beckman Coulter DxONE is most often used for a hospital laboratory standardising on beckman dxc and dxi analysers that wants autoverification to release the majority of routine chemistry without technologist review, a low volume rural laboratory that cannot justify on premises middleware servers and needs a cloud hosted rules engine, a multi site laboratory network that needs identical autoverification rules applied consistently across every site, which remisol advance is built for, a laboratory whose lis cannot express delta checks or repeat rules and needs that logic to live in middleware instead. Of those, a hospital laboratory standardising on beckman dxc and dxi analysers that wants autoverification to release the majority of routine chemistry without technologist review and a low volume rural laboratory that cannot justify on premises middleware servers and needs a cloud hosted rules engine are not what Therapixel is typically brought in for.
What can Beckman Coulter DxONE do that Therapixel cannot?
Beckman Coulter DxONE covers DxONE Command Central, DxONE Workflow Manager, REMISOL Advance, DxONE Inventory Manager. Therapixel covers MammoScreen 2D, MammoScreen DBT, One to ten suspicion score, Summary report.

Answered from the vendors’ own pages

Beckman Coulter DxONE: Can I buy DxONE without buying Beckman analysers?

Not realistically. It is quoted as part of an instrument or reagent agreement and its value is in the depth of integration with Beckman platforms. A laboratory with other analysers should look at vendor neutral middleware.

Therapixel: Is MammoScreen FDA cleared?

Yes. It holds 510(k) clearance K192854 for two dimensional mammography from July 2020, a November 2021 clearance for digital breast tomosynthesis, and two further clearances in October 2024 for later versions.

Beckman Coulter DxONE: Is DxONE the same as REMISOL Advance?

No. REMISOL Advance is the on premises middleware for higher volume and multi site laboratories. DxONE Workflow Manager is a separate cloud product aimed at low volume laboratories. They are not the same rule engine.

Therapixel: Is it CE marked?

Yes, but European buyers should ask specifically for the current certificate under the Medical Device Regulation and its expiry date, because this class of diagnostic AI moved to a higher classification under MDR.

Beckman Coulter DxONE: Does Beckman publish pricing?

No. Everything is quoted, and the software cost is usually folded into a cost per reportable result on a reagent contract rather than shown as a licence fee.

Therapixel: What does the one to ten score mean?

It is a graded suspicion score per finding and per study, designed to be integrated alongside a radiologist BI-RADS assessment rather than treated as a positive or negative result.

Beckman Coulter DxONE: Is DxONE a regulated medical device?

The middleware components carry regulatory registrations that vary by product and region. Autoverification of diagnostic results is a regulated function, so confirm the specific clearance for the module and country before deployment.

Therapixel: Does it cover anything besides mammography?

No. It is a mammography product only, including tomosynthesis. Other body regions need a different vendor.

Share

Related pages

More on Beckman Coulter DxONE

More on Therapixel

Keep looking

Other head to heads